Navigation Links
Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No

The FDA has given its consent for the novel version of the allergy medicine, Clarinex-D 12 Hour, to alleviate nasal, non nasal symptoms and nasal congestion occurring in adults and children above the age of 12. According to the // researchers, this medicine will be in time for the spring allergy season.

It is estimated that about 36 million people in the U.S. are troubled by seasonal allergies with apparent runny nose, sneezing, nasal congestion, and itchy, watery eyes, symptoms.

Clarinex (desloratadine) , used for treatment of seasonal allergy symptoms, is a nonsedating antihistamine procured only by prescription . Approval for Clarinex-D 24 Hour (containing 5 milligrams desloratadine and 240 milligrams pseudo ephedrine), prescribed only once a day was obtained last spring. Clarinex-D 12 hour, the recently approved medicine contains 2.5 milligrams desloratadine and 120 milligrams pseudo ephedrine, and can be consumed twice a day.

The FDA approval was close on the heels of two clinical trials involving 1,200 people or more who suffered seasonal allergies. The trails involved comparison of the treatment with Clarinex-D 12 HOUR extended-release tablets with pseudoephedrine alone and desloratadine alone. The results depicted that the extended-release-combined medication eased nasal congestion as well as provided immense relief compared to desloratadine alone, relieving other allergy symptoms better than pseudoephedrine alone.

Insomnia, headache, dry mouth, and fatigue are some of the common side effects associated with Clarinex-D 12 Hour use. This medicine should not be taken by those suffering from narrow-angle glaucoma, severe high blood pressure or heart disease, urination difficulty, or by patients who may have taken a monoamine-oxidase inhibitor 14 days prior to the use of this drug. It also recommended that those with certain other medical conditions such as high blood pressure, diabetes, heart disease, thyroid, liver , or kidney problems, or enlarged prostate should seek the advice of a medical specialist before resorting to the use of Clarinex-D 12 hour or Clarinex-D 24 Hour.


'"/>




Related medicine news :

1. British Doctor cleared of murder
2. Mist over a way to help premature babies breathes cleared!
3. Business model for Liver Institute cleared by Delhi Cabinet
4. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
5. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
6. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
7. US Doctors Association Gives away $110,000 To NGO’
8. Woman In Coma Gives Birth To Daughter
9. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
10. New Eye Surgery Gives Hope To Short-Sighted
11. Jharkhand Gives Health industry status
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: